Search
Heron Therapeutics Inc
HRTXAdd to Watchlist
0.438USD
+0.014+3.30%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
82.67MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.30%
5 Days
+1.18%
1 Month
-47.00%
6 Months
-66.28%
Year to Date
-66.28%
1 Year
-79.80%
Key Figures
0.440Open
0.449High
3.06MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.63%Turnover Ratio
0.424Prev. Close
0.419Low
1.03MTurnover
LossP/E Static
10.22P/B
0.00%Div Yield TTM
-12.84%ROA
2.30052wk High
1.60Volume Ratio
-13.58MNet Profit
188.58MShares
-0.1811EPS TTM
1.62Beta
-2408.88%ROE
0.73652wk Low
7.00%Amplitude
69.35%Gross Margin
82.67MMarket Cap
-1.15Reward/Risk
4.38%Risk Rate
TradingKey Stock Score of Heron Therapeutics Inc
Currency: USD Updated: 2026-07-01Key Insights
Heron Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 66 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Heron Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Heron Therapeutics Inc Highlights
StrengthsRisks
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.93% year-on-year.
Overvalued
The company’s latest PE is -2.34, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 169.55M shares, decreasing 4.55% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.39.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
2.500
Target Price
+474.05%
Upside Space
Heron Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Heron Therapeutics Inc Info
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Ticker SymbolHRTX
CompanyHeron Therapeutics Inc
CEOCollard (Craig Alexander)
Websitehttps://www.herontx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
FAQs
What is the current price of Heron Therapeutics Inc (HRTX)?
The current price of Heron Therapeutics Inc (HRTX) is 0.42.
What is the symbol of Heron Therapeutics Inc?
The ticker symbol of Heron Therapeutics Inc is HRTX.
What is the 52-week high of Heron Therapeutics Inc?
The 52-week high of Heron Therapeutics Inc is 2.30.
What is the 52-week low of Heron Therapeutics Inc?
The 52-week low of Heron Therapeutics Inc is 0.74.
What is the market capitalization of Heron Therapeutics Inc?
The market capitalization of Heron Therapeutics Inc is 80.33M.
Is Heron Therapeutics Inc (HRTX) currently rated as Buy, Hold, or Sell?
According to analysts, Heron Therapeutics Inc (HRTX) has an overall rating of Buy, with a price target of 2.50.
What is the Earnings Per Share (EPS TTM) of Heron Therapeutics Inc (HRTX)?
The Earnings Per Share (EPS TTM) of Heron Therapeutics Inc (HRTX) is -0.12.